Careers • News • Contact us •
Dec 01, 2026
From 1 PM to 2 PM
Julian Downward, PhD, FRS, FMedSci
Principal Group Leader
Oncogene Biology Laboratory
Francis Crick Institute
This conference is hosted by Jean-François Côté, PhD.
About this conference
Drugs targeting mutant KRAS, a major oncogenic driver, produce impressive short-term clinical effects, but their long-term impact is rapidly compromised by drug resistance. This has driven interest in combining KRAS inhibitors with other modalities to improve response durability. Oncogenic KRAS not only promotes cancer cell proliferation and survival but also suppresses anti-tumour immunity via cytokine and chemokine secretion, reduced antigen presentation, and suppression of tumour-intrinsic interferon responses. KRAS inhibitors relieve this suppression, profoundly remodelling the tumour microenvironment. Using optimised mouse lung cancer models mimicking clinical immune phenotypes, we see striking combination effects of KRAS inhibitors and PD-1 immunotherapies in immunogenic tumours, achieving immune-dependent eradication. In immune-cold tumours, regulatory T cells drive evasion, and combined Treg/KRAS targeting shows considerable potential. Finally, using models mimicking selection of drug-resistant sub-clones, we show that KRAS inhibitors combined with certain immune-targeted agents induce immune-mediated bystander killing of resistant sub-clones, potentially enabling generalisable approaches to drug resistance.
About Julian Downward
Julian Downward trained with Mike Waterfield and Robert Weinberg before setting up his own lab in 1989 at the Cancer Research UK London Research Institute. He moved to the Francis Crick Institute in 2016. His work focuses on the role played by major oncogenes such as RAS and EGFR in human cancer. He established that EGFR is the product of the erbB proto-oncogene and was responsible for mapping out the signaling pathways linking EGFR to RAS and downstream to the MAP kinase and PI 3-kinase pathways. He now focuses on novel approaches to targeting RAS mutant lung cancers, exploring the effects of RAS signaling on suppression of the immune system’s response to the tumour. Julian is a Fellow of the Royal Society, Academy of Medical Sciences, Academy of the AACR, and a Member of EMBO.
To make sure you don't miss any of the IRCM conferences, sign up now for our newsletter!
© Montreal Clinical Research Institute, Année.All rights reserves. | Privacy policy | Terms of use | Web site by Agence Riposte